SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
CUBIST PHARMACEUTICALS (CBST)
An SI Board Since February 1997
Posts SubjectMarks Bans Symbol
252 31 0 CBST
Emcee:  Weekapaug Type:  Unmoderated
Introduction Market Data Compact
Might be worth looking at, good alliances with alot of majors, float only about 3.5 million shares, please respond?
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
252 Cubist says 3Q profit falls, but raises outlookCubist Prichardred-10/20/2011
251I think the patent situation is pretty well boxed at this point. CBST reported kenhott-4/20/2011
250<reply> A bunch of OT for CBST, sorry. Only time for one quick reply. Rkenhott-4/19/2011
249I would think SG&A will be lower as legal patent defense is over and mitigatIRWIN JAMES FRANKEL-4/8/2011
248Cubicin is a nice little drug. Might get a pullback in price because the story kenhott-4/8/2011
247"Flagyl is first line right now." In most cases, yes. Flagyl IS cheatuck-4/8/2011
246Flagyl is first line right now. rkrw-4/7/2011
245On CBST valuation - think good news has just been priced in but not sure pipelinidos-4/7/2011
244Interesting times for Cubist. First they get a little more mileage out of Cubictuck-4/6/2011
243That didn't go too well in terms of safety, if what I see in the table is coidos-7/21/2009
242TEVA submits Paragraph-IV challenge on Cubicin: reuters.comidos-2/10/2009
241CBST signs partnership with ALNY to develop and commercialize RNAi therapeutics idos-1/9/2009
240Oppenheimer downgraded this morning; here's the color: notablecalls.blogspotuck-12/5/2008
239Late last week, iclaprim got a negative panel opinion and a couple of days ago, idos-11/28/2008
238Like rkrw have pointed out, the main use for telavancin should be in hospital aidos-11/23/2008
237Cubicin doesn't work well in HAP.rkrw-11/23/2008
236FDA decision based upon data which shows it works as well as vancomycin but saystelephonics-11/23/2008
235One competitor in (telavancin), the other one out (oritavancin) and one more to idos-11/20/2008
234UPDATE 1-<b>Cubist posts higher Q3 profit on Cubicin sales</b> reutidos-10/17/2008
233It wasn't reimbursed?DewDiligence_on_SI-8/22/2008
232My wive underwent three weeks of cubicin intravenous treatments. It was a very telephonics-8/22/2008
231For Cubist, a Tough Sell (article from today’s Boston Globe): siliconinvestor.DewDiligence_on_SI-8/18/2008
230Better-than-expected 2Q U.S. Cubicin sales and CBST raised its ’08 Cubicin salesidos-7/19/2008
229Forest's ceftaroline, a potential competitor to Cubicin, proved not inferioridos-6/19/2008
228Read the latest company filing with the SEC. Super performance. The company shoutelephonics-4/19/2008
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News